Dimitrov D
Vutr Boles. 1984;23(4):65-9.
Peroral treatment with rhythmonorm (Knoll AG--GFR) with 450 to 900 mg daily was carried out to 38 patients with an average age 52,2 +/- 2,34, with chronic ventricular extrasystole. In 89,50 per cent of the cases, complete inhibition of the ventricular extrasystoles was attained or reduction in their number with greater than 80 per cent, and that result, in 55,26 per cent, was attained within the first days of the treatment. The pulse rate was reduced with 10 per cent on the average by the end of the treatment. Significant changes in cardiac conductivity, arterial pressure and severe adverse effects were not observed. The preparation rhythmonorm is an effective, convenient to take and well tolerated agent for the treatment and prophylaxis of ventricular extrasystoles.
对38例平均年龄为52.2±2.34岁的慢性室性早搏患者进行了口服利搏律定（诺尔股份公司——肾小球滤过率）治疗，每日剂量为450至900毫克。在89.50%的病例中，实现了室性早搏的完全抑制或数量减少超过80%，并且在55.26%的病例中，在治疗的头几天内就取得了该效果。到治疗结束时，平均心率降低了10%。未观察到心脏传导、动脉血压的显著变化以及严重不良反应。利搏律定制剂是一种治疗和预防室性早搏的有效、服用方便且耐受性良好的药物。
